Skip to content

Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-515527-11-00
Acronym
ORIC-944-01
Enrollment
48
Registered
2025-02-03
Start date
2025-03-20
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Sponsors

ORIC Pharmaceuticals Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026